title: Viral hepatitis C in 2014--the beginning of the end?
authors: Cristina Cijevschi
authors: CC
authors: Prelipcean
authors: P
authors: P
authors: Gogălniceanu
authors: Cătălina
authors: C
authors: Mihai
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D014943:Global Health; D016174:Hepacivirus / Q000302:isolation & purification / Q000472:pathogenicity*; D006526:Hepatitis C / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D009842:Oligopeptides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015995:Prevalence; D011392:Proline / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000627:therapeutic use; D012383:Romania / Q000453:epidemiology; D014944:World Health Organization
chemical_list: D000998:Antiviral Agents; D007370:Interferon Type I; D009842:Oligopeptides; D011480:Protease Inhibitors; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D011392:Proline